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ABSTRACT 
Gene therapy has been initiated as long back from 1990s but is still in development. Research has been continuously going on in this field in order to 
cure genetic diseases by various techniques. One of these is aptamers. Aptamers are single stranded DNA or RNA molecules made by SELEX 
technology and have the ability of attaching to a variety of targets namely proteins, peptides, carbohydrates, toxins etc. They find application in 
skeletal disorders, biosensors, detection of viruses, delivery of drugs, various drug delivery systems, etc. 
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INTRODUCTION 
Humans have been suffering from diseases since ancient times, 
which includes external ones like Scabies, Ringworm, Chickenpox 
and so forth as well as internal ones like Influenza, Pneumonia, 
Acquired Immuno Deficiency Syndrome (AIDS) etc. Though treating 
some of them is not easy but most challenging to cure are disorders 
known as genetic disorders, which arise due to mutation in genes or 
defective genes with which a person is born with due to passing on 
the genes from either of the parents coupled with many 
environmental factors which also play a role in pathogenesis of the 
disorder. These disorders although scarce, have an impact on 
millions of people all over the world. Examples include Lesch Nyhan 
Syndrome, Down’s syndrome, Cancer and Sickle cell anemia to name 
a few. In order to remedy such disorders, we require gene therapy. 
Gene therapy has been defined as introduction of nucleic acids into 
cells to treat, repair or replace and regulate defective genes to treat 
genetic diseases. The newly encoded nucleic acids will correct the 
faulty protein synthesis and the deficiency in the protein which was 
leading to the disease will be corrected [1]. There are many 
approaches towards this treatment like by employing antisense 
oligonucleotides, aptamers, liposomal gene delivery etc. Out of them, 
one such approach is by aptamers, which are defined as short single 
strand nucleic acid molecules, comprising of Deoxyribose Nucleic Acid 
(DNA) or Ribose Nucleic Acid (RNA) that attach to organic or inorganic 
molecules ranging from single atoms to an extensive variety of 
proteins. Aptamers are known by their high specificity to target 
molecule and binding power: dissociation constant of aptamer/target 
molecule complex comprising of repeated nanomolar units of RNA or 
DNA bases is high so that they do not separate easily [2]. Due to the 
advancements in Systematic Evolution of Ligands by Exponential 
Enrichment (SELEX), which is now a fundamental technique for the 
separation of aptamers, multiple aptamers can be instantly selected in 
vitro against many targets, ranging from compact biomolecules to 
proteins and even on a cellular level [3]. The adoption technique of 
aptamers SELEX is an in vitro method. Briefly, SELEX is based on 
repetitive cycles of binding, splitting and multiplication of nucleotides. 
The primitive step of traditional SELEX is to cultivate the sequence 
pool with the target (protein, nucleic acid, etc.). The sequence pool 
comprises of nucleic acid library containing 1014-1015
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random 30–100 nucleotides surrounded by persistent sequences at 
both ends. The casual region accommodates the sequences that will be 
evaluated for top specificity and affinity to the target. Second step if 
that the sequences that attach successfully to the target are retained, 
while unbound nucleotides are released from the cycle. The third step 
is to cleanse and multiply the fused sequences to form a novel 
sequence pool for the next cycle. This cyclic process is usually 
repeated 8–15 times before attaining the appropriate aptamer 
sequence pool which is needed to complete the process [4, 5]. 
Literature survey was done using accessible databases such as Google 
scholar, PubMed, Scopus to combine research articles. The objective of 
this review is to provide all the literature on aptamers in the last 10 y 
followed by their applications. 
The structure of aptamer used therapeutically is given below as 
shown in fig. 1. 
 
 
Fig. 1: Structure of aptamer pegaptanib (Macugen), the foremost nucleic acid aptamer to be given permission by the US FDA for clinical 
use [6] 
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Adapted by permission from the ATD Bio (Chemical industry in 
Southampton, England) 
Aptamers are novel target molecules for therapeutic intervention 
and diagnostic, aptamer technology has a great potential to become 
a source of lead compounds. For an assembly of aptamers there is no 
need any animals or specific cell lines; thus they can be pushed up 
against noxious molecules or non-immunogenic targets with apex 
rapport and specificity [7]. The characteristics of bacterial virus 
phi29 packaging RNA (pRNA) molecules were employed to unite it 
with a hexameric ring nanostructure of aptamer, thereby inclined 
towards delivering multiple therapeutics into specific cells [8]. 
Experiment involving adding different receptor-binding ligands to 
pRNA double-stranded 5´/3´end helical domain resulted in chimeric 
molecules such as pRNA/aptamer [9]. DNA nanostructures can also 
be influenced to fabricate molecular machines of variable 
complexities. These molecular devices can be run to liberate many 
types of cargos at specific targets by conformational switching. This 
conformational change is induced by a molecular effector or by 
intermolecular hybridization with complementary nucleic acids. 
Aptamer-based biosensor technology is the energetically-growing 
aptamer field and pledges to continuously pop up with new clinical 
or twin drug diagnostic and personalized theranostic assays. A lot of 
academic laboratories exploit the capacity of aptamers to change 
their conformation upon ligand binding to develop label-free 
analytical assays [10]. A construct which is able to detect avian 
influenza virus reserved as aptasensor was developed. Quartz 
crystal microbalance (QCM) method was used, which includes 
attachment of quartz particles to the polymeric, porous hydrogel, 
containing DNA aptamers. Not long ago, the avian influenza was an 
epidemiological hurdle; the disease hereby designated by a severe 
course, high mortality rate and escalated risk of zoonotic influenza 
strain production. It has the ability of being transmitted from one 
person to person. Hemagglutinin (HA), a popular influenza protein 
typically a glycoprotein present in pinnacle amounts on the viral 
surface and is the cause for amalgamation of the virus with the host 
cell. There are a minimum of 18 variable HA antigens; therefore, 
they could serve not only for infection discovery in addition to 
differentiate between current influenza types and subtypes. 
Aptamers are able to decide between influenza types A from type B 
or even allied strains of the same influenza subtype. It should be 
noted that P30-10-16 lashes to the target molecule (H3N2 of virus 
A) with more than 15-fold elevated affinity, as compared to standard 
anti-HA monoclonal antibody. Just now, aptamers were 
manufactured which are able to detect influenza virus type A: H1N1 
and H3N2, along with avian virus, H5N1. It is still indispensable to 
make simple and widely available methods in order to further 
expand the benefits of aptamers. Another salient area of applications 
of aptamers is the detection of chronic infections caused by viruses 
of hepatitis B and C [11]. Aptamer specific for HCV E2 glycoprotein 
was unearthed, which brought into light a novel diagnostic test—
Enzyme-Linked Apto-Sorbent Assay (ELASA)—which permitted for 
qualitative analysis, in addition to quantification of virus particles in 
the assessed samples [12]. An important impact for expansion in 
viral diagnostics with aptamers have been made possible by 
constructing gold microelectrodes with impedimetric properties in 
order to decide between biologically active from inactive form of the 
virus and used heat-inactivated vaccine as a prototype. Using fixed 
set of DNA aptamers which were exposed, the presence of the viable 
virus form could be identified since the probability of error was 
lowered significantly [13]. Similar study was taken up, which in turn 
defined the target of constructed aptamer as a glycosylated HA 
available on infected cells. It is important to blossom the line of fast, 
quick responding, and economically diagnostic tools, to pinpoint the 
type of virus infection, as well as detection of dysplastic endometrial 
cells with the hazard of malignant metamorphosis. As a, HPV is a 
prospective target for aptamers [14]. An experiment done by making 
use of in vitro selection to obtain the RNA aptamer that tethers to 
viral E7 oncoprotein. Being a section of the biosensor it could equip 
a powerful diagnostic tool which helps to detect virus within the 
human body [15]. A fluorescent-conjugated DNA aptamer was 
developed that has the power to bind surface determinants of the 
normal cervical epithelium. The cells that started malignant 
transformation failed to fuse with the aptamer [16]. DNA aptamers 
were constructed, which were targeted as antagonists towards the 
pathogens of the arbovirus family, including a variety of viruses, 
such as Chikungunja, Crimean-Congo Hemorrhagic Fever, Dengue, 
West Nile and Tick-Borne Encephalitis. They got sequences with 
high precision and rapport for both the clean recombinant viral 
proteins and whole inactive viruses. They demonstrated the merit of 
chosen sequences in forecasted diagnostic methods, i.e., lateral flow 
chromatographic test strip and fluorescent aptamer-magnetic bead 
sandwich assay. They also brought forward the aptamers to be 
serviced for pliant immunity and antiviral prevention because of the 
shallow immunogenicity. This technique could be bright in any 
dangerous infection with shortfall of well-organized therapeutic 
replacement. The application of biosensors loaded with the 
aptamers or differing research techniques by adopting these 
molecules permits for sensing of both: early (genetic material, viral 
proteins) and late (host own antibodies) infection markers [17]. 
There is a high probability of infection and astonishing frequency of 
mutations, leading to a cyclical emergence of novel viral strains with 
epidemic or even pandemic danger as a result focused attention was 
given to influenza diagnosis. It is still necessary to generate simple 
and available technics in order to increase the benefits of aptamers 
[18]. To weaken HIV-associated cardiomyopathy an anti-
glycoprotein120 aptamer called as UCLA1 was established. It 
directly fuses to HIV-1 thereby destroying the virus, thus granting 
cardiomyocytes from cell death and indirectly halted infection of 
monocyte-derived macrophages in the heart [19]. 
Diagnostic works with aptamer-based biosensors performed on 
natural or clinical-based samples 
The efficacy of aptasensors in the recognition of viruses was also 
evaluated in clinical samples. An experiment was undertaken to 
merge aptamers with biosensor technology, known as Surface 
Plasmon Resonance (SPR). This model incorporates a fragment 
coated with both gold coting and Streptavidin as the drug. DNA 
aptamers launched against avian influenza H5N1 have been fixed to 
its surface, since they were reconstructed by biotinylation; the 
material altered in the study was saliva collected from the poultry. 
The method has absence of labeling procedures and enables quick 
(1.5 h) detection [20]. In another study twin aptamers called as IF10 
and IF22 were constructed, became attached at different sites of 
H5N1 virus, and playing a dual role of capturing probe as well as 
signaling probe, respectively. This resulted in a sandwich-type SPR 
biosensor platform for the sensitive detection of H5N1 viruses. The 
aptasensor, consisted of H5N1 virus attached to a biotin-labeled 
aptamer IF10, which was strapped onto the surface of the 
streptavidin-coated SPR gold chips. The detection ability shown by 
this aptamer was comparable to that of Enzyme-linked 
immunosorbent assay (ELISA) [21]. A solitary-molecule real-time 
aptasensor for recognizing HIV-1 was constructed. This study 
employed a combination of Nano pores, resistive-pulse technique, 
and an RNA aptamer which is specific towards the HIV-1 
nucleocapsid protein 7 known as SL3. A voltage was passed across a 
silicon nitride membrane, and the strength of the ionic current 
flowing through the nano-pores on the membrane was assessed. The 
passage of aptamer-protein complex through the membrane, 
interrupted the current, which was in turn restored by a 
translocation event signal thus confirming the presence of the 
protein and subsequent detection of the virus [22]. 
Pros and cons of aptamer-based tests in comparison to other 
diagnostics methods 
The ongoing diagnostic methods for detection of viral infections are 
mostly ELISA or molecular biology tests, which are routinely employed 
[20, 23, 11, 14]. Repeatedly used ELISA is a multi-stage method and is 
less efficient due to the fact of relatively shallow sensitivity as well as 
high incidences of false-positive results [20, 23, 11]. As a substitute 
regularly used or even investigational diagnostic molecular tests 
permit for quickest detection of the new genetic material, without 
standing by for the immune reaction of the host. Furthermore, the 
supremacy of molecular assays is their very high sensitivity: they 
have the ability to catch lone viral copies and/or early viral 
transcripts right away after the genesis of infection [25, 26]. But 
these have their shortcomings such as not economically feasible, 
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complex procedures and requiring trained persons, as well as they, 
are hardly ever used in practice. Aptamers seem to be an 
appropriate solutions to the hindrances described above. They show 
light as a stunning alternative to the traditionally used procedures, 
due to their high specificity, power of binding to whichever comes to 
hand viral antigen and low cost of manufacture. The application of 
biosensors armed with the aptamers or additional research methods 
using these molecules permits for detection of both: newly 
manifested (genetic material, viral proteins) and delayed (host own 
antibodies) infection markers [23, 24]. Also, aptamers allow to 
choose between infected host cells and not infected ones and maybe 
supportive to point out active incarnations of the virus [13, 16]. 
Table 1 compares a few of the traditional diagnostic techniques 
employed in the recognition of influenza, HBV and HIV as given 
below. It is worthwhile to note that in many scenarios, the use of 
currently available diagnostic tools has a number of limitations, which 
can be bypassed using aptamers [27, 28]. Moreover, the aptamer-
based minimum boundary of detection is occasionally lesser than in 
RT-PCR, in the case of influenza virus [11, 27]. In contrast, when the 
detection threshold is indistinguishable, or even more as compare to 
modern used techniques, and aptamers guarantee enhanced 
sensitivity as well as specificity of the diagnostic assay [20]. 
 
Table 1: Comparison of traditionally used diagnostic techniques in the detection of HIV, HBV and influenza 
Virus Method Detection limit Advantages Disadvantages References 
Influenza RT-PCR 0.0256 HAU/ml Specificity Expensive Dhumpa R et al.2011 [27]. 
qRT-PCR 1.785 IU/ml Sensitivity Complicated, highly skilled stuff Sidoti F et al. 2010 [28]. 
HBV ELISA 0.5 pg/ml Specificity Expensive Yang J et al. 2010 [29]. 
qRT-PCR 18 IU/ml Sensitivity Complicated, highly skilled stuff Kim H et al. 2013 [30]. 
HIV ELISA 0.9–1.2 IU/ml Specificity Expensive Mühlbacher A et al. 2013 [31]. 
qPCR 3.21–11.60 IU/ml Sensitivity Complicated, highly skilled stuff Saune K et al. 2013 [32]. 
 
Applications of aptamers 
Aptamers in bio imaging 
One application of aptamers is in bio-imaging, where employing an 
aptamer that is fused to a fluorophore, a quantum dot (QD) or other 
materials such as gadolinium which is functional for magnetic 
resonance imaging (MRI). Using aptamers as imaging agents has the 
superiority of being non-toxic due to the fact oligonucleotide 
moieties exist in the human body. Results were published of glioma 
cell line (C6) cell imaging using a dye called as Cyanine 3(Cy3) which 
was labeled onto AS1411 aptamer, which had undergone chemical 
modification of 5-(N-benzylcarboxyamide)-2′-deoxyuridine (5′-
BzdU) on a thymidine base. The AS1411 aptamer is particular for the 
nucleolin trans-membrane protein present in cancer cells. 
Specifically, this group enhanced the aptamer’s binding power to its 
target via a chemical modification. The cell imaging of the altered 
Cy3-labeled AS1411 aptamer was more systematic for the C3 cells as 
compared to the original Cy3-labeled AS1411 aptamer [33]. 
Assembly of QD-A10 and DUP-1 aptamer complex was done, which 
is particular for Prostate-specific membrane antigen [PSMA (+)] and 
[PSMA (−)] prostate cancer cells (LNCaP and PC3), was 
demonstrated by imaging to attach only to prostate cancer cells 
instead of normal (PNT2) or other cancer cells [34]. 
Aptamers in delivery of anthracycline drugs and imaging 
The majority of theranostic studies with aptamers involve the co-
delivery of imaging agents in addition to anthracycline drugs 
(predominantly Doxorubicin). These drugs deal with DNA by 
intercalation, halting replication, and disrupting gene expression. 
The first way to administer the drugs was to entrap them in different 
types of nanoparticles that were further labeled for recognition by 
imaging by attaching to aptamers. This method was used where 
doxorubicin in mesoporous silica nanoparticles that were further 
bonded with an anti-MUC1 aptamer and radiolabeled by [99] 
Technetium. Fixed targeting in addition to drug delivery of the 
nanoparticle was exhibited in vitro on cells and scintigraphy 
demonstrated that the nanoparticles were able to choose a 
subcutaneous tumor in vivo [35]. A similar strategy was used where 
in the loading of superparamagnetic iron oxide nanoparticles 
(SPIONs) and Doxorubicin in poly (lactic-co-glycolic acid) (PLGA)-
based nanoparticles were done which were further joined to the 
anti-nucleolin aptamer. Higher tumor targeting was achieved by MRI 
for the nanoparticles bonded with the aptamer than for non-bonded 
nanoparticles. Additionally, the nanoparticles bonded with the 
aptamer gave much higher inhibition of tumor growth and ensured 
the sustained life span of mice having C26 colon carcinoma 
xenografts [36, 37]. Yet another procedure to administer drugs is to 
permanently attach them to the surface of nanoparticles. This 
strategy was employed to bond an anti-MUC1 aptamer to quantum 
dots and further joined Doxorubicin to their surface via a pH-
sensitive hydrazone bond. These bonds do not break down in blood 
at a neutral as well as slightly basic pH but undergo fast hydrolysis 
in the acidic surrounding of endosomes. As a result it should free the 
drug only in cancer cells that have nucleolin because they should 
incorporate the nanoparticles via the aptamer. In vivo fluorescence 
imaging showed that the quantum dots amassed more in 
subcutaneous xenografts when they were joined to the aptamer. 
Furthermore, the therapeutic response of these nanoparticles were 
enhanced marginally by the aptamer in vitro, but was not assessed in 
vivo due to some issues [38]. Doxorubicin was also joined to the 
surface of shining gold nano-clusters which was further bonded with 
two specific targeting moieties: the anti-nucleolin aptamer and a 
cyclic Arg-Gly-Asp (cRGD) peptide, which joins to αvβ3 and αvβ5 
integrins, which are overexpressed within tumor endothelial cells. In 
vivo fluorescence imaging showed considerable higher tumor 
targeting when the nanoparticles were joined with the dual 
targeting agents than when they were lonely and somewhat greater 
tumor-targeting than nanoparticles bonded with the only cRGD. 
Intravenous injection of the nanoparticles bonded with the dual 
targeting agents every 48 h generated higher retardation of tumor 
growth than non-bonded nanoparticles and also on Doxorubicin 
alone [39]. An aptamer that bonds to the prostate-specific 
membrane antigen (PSMA), which is overexpressed on several 
prostate tumors was developed. The extension the sequence of the 
aptamer by an auxiliary (CGA) 7 repeat that was inter-mixed to a 
sequence conjugated earlier to the surface of SPIONs was 
performed. This dual strand matching was used to conjugate the 
aptamer as well as for the entrapment of Doxorubicin, which is 
known to preferably attach to following cytosine and guanine base 
pair regions. The biodistribution of this complex was then checked 
by MRI in nude mice showing subcutaneous tumors. Following an 
hour after administration the nanoparticles bonded with the 
aptamer showed ten-fold greater tumor-targeting than those joined 
with a scrambled control sequence [40]. A similar loading strategy 
employed which involved entrapment of a MUC1 aptamer that was 
joined to SPIONs, with Epirubicin. MRI demonstrated higher tumor 
targeting of the nanoparticles conjugated with the aptamer than 
unconjugated nanoparticles, similarly to the previous study. 
Furthermore, they also demonstrated greater retardation of tumor 
growth [41]. The ability of Doxorubicin to intercalate into DNA was 
also exploited to construct an intelligent split aptamer-based 
activatable theranostic probe. They employed the Sgc8c aptamer 
that deals with a cancer-related membrane PTK-7. The Sgc8c 
aptamer was broken into two parts and joined via a short DNA 
linker labeled with a fluorophore. The central part of this linker was 
then inter-mixed with a complementary short DNA strand to which 
was linked to a quencher that diminishes the fluorescence emission 
of the fluorophore. It was also armed with Doxorubicin, as the 
double helix region linker/short DNA strand was guanine and 
cytosine rich. The model was designed to be pulled apart when the 
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structure of the aptamer encounters metamorphosis during its 
interaction with PTK-7, delivering the Doxorubicin and activating 
the radiation of a fluorescent signal. Both therapy as well as imaging, 
were tested in vitro. The checking of the construct in vivo by 
fluorescence imaging in nude mice bearing subcutaneous tumors 
was also carried out. The tumor demonstrated high fluorescence, 
just 15 min post-injection, but the clinical response was not 
evaluated [42]. 
Aptamers in delivery of taxane drugs and imaging  
An overview of aptamers employed in various drug delivery 
systems, including cancer and other diseases, is shown in fig. 2. 
 
 
Fig. 2: An overview of various aptameric systems used in drug delivery [43], A] Entrapment of aptamer drug complex in liposome, B] 
Aptamer antibody conjugate for targeting selective genes, C] Drug streptavidin serving as a base for connecting two aptamers and two 
siRNA molecules, D] Drug 5-flourouracil shown in red connected to the aptamer oligonucleotide backbone via a photocleaveable linker 
which is shown in blue, E] Chemical structures of Tobramycin (red) and Doxycycline (blue) 
 
Copyright permission obtained under creative commons (CC 
BY) license (http://creativecommons.org/licenses/by/4.0/) 
Several theranostic studies have been conducted with aptamers for 
the co-delivery of imaging agents and taxane drugs, such as 
Paclitaxel (Taxol) and Docetaxel (Taxotere), which are commonly 
employed as chemotherapy agents. The main mechanism of action of 
these drugs is to wreak havoc upon the microtubule duty that is 
pivotal for cell division. Opposite to anthracyclines, which are water-
soluble, taxanes are water-insoluble. Thus, the theranostics 
nanosystems were designed for those drugs which are not alike. A 
method was established using a nano-precipitation process with an 
acetone/water system to build nanoparticles of cholic acid-derived 
with a star-shaped block copolymer comprising of polylactic glycolic 
acid (TPGS) and Vitamin E armed with Docetaxel and a near-infrared 
fluorescent dye. The surface of these nanoparticles was moreover 
linked with the anti-nucleolin aptamer. The constructed 
nanoparticles were checked in two mouse models wherein the mice 
obtained subcutaneous tumor xenografts from human breast cancer 
cell lines. The nanoparticles linked with the aptamer showed four-
fold higher tumor-targeting 24 h following after intravenous 
injection than non-bonded nanoparticles or free dye by fluorescence 
imaging. Furthermore, they also illustrated higher inhibition of 
tumor growth [44]. The anti-nucleolin aptamer was also exploited 
again to target poly (L-c-glutamyl-glutamine) nano-conjugates 
armed with Paclitaxel as well as a fluorescent dye. In contrast to 
most of the studies described above, these nanoparticles were not 
checked in subcutaneous models but in nude mice that institute 
orthotropic brain tumors from an intracranial injection of human 
U87 MG glioblastoma cells. Fluorescence imaging showed two-fold 
higher tumor targeting by the nanoparticles linked with the aptamer 
than lone nanoparticles 24 h following intravenous injection. 
Additionally, when the nanoparticles were administered every three 
days, the median life span of mice that obtained the nanoparticles 
(52 d) was substantially prolonged as compared to those treated 
with unconjugated nanoparticles (47 d), free Taxol (40 d), or a 
control saline solution (36 d) [45]. Not so different conclusions were 
seen in an alternative orthotropic brain tumor model. The also 
similarly employed the anti-nucleolin aptamer joined to the surface 
of poly (ethylene glycol)-poly (ε-caprolactone) nanoparticles armed 
with Docetaxel and fluorescence dye. The surface of the nanoparticle 
was also joined with a peptide earlier protected by phage display to 
travel across the Blood-Brain Barrier (BBB). Fluorescence imaging 
illustrated that this peptide improved brain ingestion of the 
nanoparticles as well as the addition of the aptamer, further 
enhanced ingestion of the nanoparticles by the tumor [46]. The same 
nanoparticle was used, which in turn attained the same result using 
an alternative aptamer chosen to recognize glioblastoma cancer cells 
in the absence of the peptide to travel across the BBB. This may be 
accountable to the truth that BBB is imaginarily hampered 
throughout the development of the brain tumor [47]. 
Aptamers in miscellaneous applications 
Hydrogels are inter-linked polymers comprising of a 3 Dimensional 
(3D) network. It is true that hydrophilic group is often present in 
chemical structures of many compounds, including hydrogels 
contain groups such as carboxylic acid (COOH), imine (NH), hydroxyl 
(OH), sulphonic acid (SO3H) and carboxamide (CONH), hydrogels 
also possess the capability to hold and absorb a fixed amount of 
water which leads to their swelling when they come in contact with 
water thus forming the 3D network [48]. Aptamer-derived 
hydrogels can be scheduled to deliver many and multiple 
therapeutics when required through particular nucleic acid 
identification and complementary inter-mixing process. Recently a 
nucleic acid-based affinity hydrogel system for controlled protein 
release was assembled. Two variable nucleic acid aptamers, as well 
as complementary sequences, were employed to control the delivery 
speed of Vascular Endothelial Growth Factor (VEGF) and platelet-
derived growth factor having two B subunits (BB) in vitro [49–51]. A 
novel aptamer-functionalized hydrogel for controlled cell capture 
and liberation was fabricated. The customizable hydrogel comprises 
of a chief Complementary Sequence (CS), which is an aptamer 
sequence and a subsidiary CS. Firstly, the main CS was linked to the 
hydrogel resting on a solid support surface. The aptamer was inter-
mixed with the key CS and can only bind bond with cells via 
polyvalent aptamer-protein interactions. When the secondary CS 
was applied to trigger the hydrogel, the aptamer broken apart from 
the main CS and then inter-mixed with the subsidiary CS. Therefore, 
polyvalent interactions between the cells and the hydrogel were 
diminished, resulting in a safe release of the cells from the solid 
surface [52]. An aptamer-derived hydrogel as a synthetic 
Extracellular Matrix (ECM) for cell fixing without compromising cell 
viability was fabricated [53]. 
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Aptamers for skeletal disease therapy in preclinical studies 
Stem-cell-based therapies are one of the most innovative and 
rewarding fields of making advancements in the treatment of 
diseases in humans [54]. Stem cells are those cells which are in their 
premature state and have not yet been differentiated to handle a 
specific task. These cells are also immortal owing to their inability to 
age over time coupled with the ability to keep multiplying forever 
and such cells have the power to transform to variable cell types like 
skin, liver, kidney, heart, nerve cells and so forth depending upon the 
type of organ in which they are introduced [55]. The cell count of 
bone marrow mesenchymal stem cells (BMSCs) is diminished 
through aging while enhanced through adipocyte polarity. It is 
already demonstrated that miR-188 level is much greater in BMSCs 
in old as compared to young mice and human. Animals deficient in 
miR-188 can be safeguarded from age-related bone loss and fat 
collection in bone marrow. An aptamer that only recognizes BMSCs 
is constructed and linked with miR-188 to form a nano complex was 
constructed. This targeted transported nano-complex could enhance 
bone generation and lessen fat collection in bone marrow with more 
clinical results in aged mice, showing a promising approach for age-
related bone loss cure [56]. Another preliminary study gave birth to 
a windowed aptamer targeted against human jaw periosteal cells 
(JPCs) is constructed for tissue engineering in oral and maxillofacial 
surgery. This aptamer has great power to bind to human 
osteogenically generated JPCs and BMSCs from bone marrow while 
it shows an absence of binding to any other cell lines or 
undifferentiated JPCs or JPCs born from alternative sources. It can be 
used to cleanse osteogenic parent cells from undifferentiated JPCs or 
stem cells from another sources. The mineralization ability is greater 
in the positive aptamer group, which is an encouraging method for 
tissue engineering [57]. 
CONCLUSION 
In order to materialize a proper therapy for genetic diseases it is 
necessary to understand what those diseases are and how they can be 
treated using methods such as aptamers. The literature work done in 
aptamers and subsequently its applications were discussed. This 
article will definitely help all researchers, students, as well as 
academicians who are working in this field. Even now advancements 
are currently going on in this field and in the future further 
developments will ensure that genetic diseases are cured successfully 
and people who are suffering from this disease will lead normal lives. 
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